# Antisecretory Factor in Primary Glioblastoma 1

> **NCT04116138** · PHASE1,PHASE2 · COMPLETED · sponsor: **Peter Siesjö** · enrollment: 8 (actual)

## Conditions studied

- Glioblastoma
- Cerebral Edema
- Chemotherapy Effect

## Interventions

- **DIETARY_SUPPLEMENT:** Salovum

## Key facts

- **NCT ID:** NCT04116138
- **Lead sponsor:** Peter Siesjö
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2021-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04116138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04116138, "Antisecretory Factor in Primary Glioblastoma 1". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04116138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*